Tag: Sunitinib

Biomarkers for treatment of renal cell carcinoma

Trial
Phase 3, CLEAR, KEYNOTE-426, IMmotion010
Conference
ASCO 2024
Type
Peer-reviewed article

18 July 2024 14:00

TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC

Presented By
Prof. Janet Brown, University of Sheffield, UK
Trial
Phase 2, STAR
Conference
ESMO 2021
Type
Peer-reviewed article

19 November 2021 09:26

CLEAR trial: promising new combination to treat RCC

Presented By
Dr Alain Ravaud, Centre Hospitalier Universitaire de Bordeaux, France
Trial
Phase 3, CLEAR
Journal
Physician’s Weekly
Conference
ASCO GU 2021

15 April 2021 16:19

CheckMate 9ER offers RCC new frontline option

Presented By
Prof. Toni Choueiri , Dana Farber Cancer Institute, Harvard University, Boston, USA
Trial
Phase 3, CheckMate 9ER
Journal
Physician's Weekly
Conference
ESMO Virtual Congress 2020

13 April 2021 16:01

ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib

Presented By
Dr. David Cella , Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, USA
Trial
Phase 3, CheckMate-9ER
Journal
Physician’s Weekly
Conference
ASCO GU 2021

13 April 2021 15:44

Superior clinical outcomes and QoL with nivolumab plus cabozantinib in RCC

Presented By
Prof. David Cella, Robert H. Lurie Comprehensive Cancer Centre, Northwestern University, Illinois, USA
Trial
Phase 3, CheckMate 9ER
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:53

Lenvatinib plus pembrolizumab prolongs survival in renal cell carcinoma

Presented By
Dr Robert Motzer, Memorial Sloan Kettering Cancer Centre, New York, USA
Trial
Phase 3, CLEAR
Conference
ASCO GU 2021
Type
Peer-reviewed article

24 March 2021 14:53

CheckMate 9ER offers RCC new frontline option; perspectives from the study’s principle investigator

Principal Investigator
Prof. Toni Choueiri, Dana Farber Cancer Institute, Harvard University, Boston, USA
Trial
Phase 3, CheckMate 9ER
Conference
ESMO Virtual Congress 2020

15 December 2020 15:49

First-line treatment of advanced/metastatic RCC

Conference
ESMO 2020
Type
Peer-reviewed article

25 November 2020 14:44

KEYNOTE-426: no QoL differences pembrolizumab + axitinib versus sunitinib

Presented By
Prof. Jens Bedke, University of TĂĽbingen, Germany
Trial
Phase 3, KEYNOTE-426
Conference
EAU 2020
Type
Peer-reviewed article

20 August 2020 10:41

Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours

Presented By
Prof. Bernhard Escudier, Gustave Roussy Cancer Campus, Paris, France
Trial
CheckMate 214
Conference
ASCO 2019
Type
Peer-reviewed article

15 July 2019 12:49
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com